{"id":"W2581312672","doi":"10.1182/blood.v114.22.3295.3295","title":"Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials).","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Nilotinib; Medicine; Tolerability; Imatinib; Internal medicine; Adverse effect; Imatinib mesylate; Myeloid leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001637577,0.0002304559,0.0004560417,0.0001917252,0.0003011192,0.0004353514,0.0001677636,0.0002874975,0.001974086],"category_scores_gemma":[0.001134132,0.0001488155,0.0002382939,0.0002894099,0.0002221148,0.0002604396,0.0002673268,0.0004296649,0.0004278592],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004017768,"about_ca_system_score_gemma":0.0005024984,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008169704,"about_ca_topic_score_gemma":0.002195243,"domain_scores_codex":[0.9995738,0.0002074541,0.00004447153,0.00004992235,0.00007191589,0.00005249204],"domain_scores_gemma":[0.9991633,0.0002250882,0.0001911268,0.00005106039,0.0001256383,0.0002437814],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2083363,0.009675455,0.5278959,0.001019135,0.0008180965,0.003901011,0.001126318,0.002139802,0.05571688,0.0005667043,0.02567835,0.1631261],"study_design_scores_gemma":[0.01964329,0.08107054,0.8550614,0.00009377309,0.0004806491,0.005304365,0.0003487222,0.001943549,0.006551973,0.0001913126,0.02926314,0.00004728153],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947705,0.001457236,0.0001294765,0.0001513822,0.00002445072,0.0002053409,0.0009746347,0.0000190945,0.002267806],"genre_scores_gemma":[0.995329,0.0004806128,0.000333804,0.0003146615,0.00004723578,0.0001614318,0.002390071,0.000006696161,0.0009363826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001974086,"threshold_uncertainty_score":0.008660436,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0551837068716041,"score_gpt":0.3749707380968654,"score_spread":0.3197870312252613,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}